Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 14/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9256008 | 0.89 | DPP8 (0.40) | DPP8DPP9NAMPTSLC40A1TIPARP | |
| SCHEMBL9256079 | 0.85 | DPP8 (0.40) | DPP8DPP9NAMPTTIPARPFFAR4 | |
| SCHEMBL9257457 | 0.81 | DPP8 (0.39) | DPP8DPP9NAMPTTIPARP | |
| SCHEMBL9252075 | 0.76 | HRH3 (0.44) | DPP8DPP9NAMPT | |
| SCHEMBL9259812 | 0.74 | GRIA2 (0.39) | DPP8DPP9NAMPTSLC40A1FFAR4 | |
| SCHEMBL9252927 | 0.74 | MMP2 (0.35) | DPP8DPP9SLC40A1FFAR4GRIA2 | |
| SCHEMBL9963375 | 0.71 | DPP8 (0.46) | DPP8DPP9NAMPTTIPARP | |
| SCHEMBL171403 | 0.70 | MAOA (0.43) | DPP8DPP9NAMPTTIPARP | |
| SCHEMBL9255195 | 0.69 | CACNA1H (0.43) | FFAR4 | |
| SCHEMBL16219056 | 0.69 | DPP8 (0.67) | DPP8DPP9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | DPP8 2312/4885DPP9 1589/4885NAMPT 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.